A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin/Carboplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck

Trial Profile

A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel And Cisplatin/Carboplatin With Or Without Erlotinib In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of the Head And Neck

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.
    • 12 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 01 May 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top